Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

Andrzej Jakubowiak, MD, PhD
Published: Wednesday, Sep 14, 2016



Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.


Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x